After the previous idea, which concluded successfully, I am coming back to Moderna, which is included among the BIOTECH stocks I am following most closely.
Some background information:
Moderna is first and foremost a research‑driven biotechnology company, not a traditional, mature pharmaceutical firm. Its value does not depend on stable revenues or on a single product, but on its mRNA platform and its ability to turn scientific research into new therapies and vaccines.
The market today tends to view Moderna as a declining ex‑COVID stock, but this perspective underestimates its nature as a platform‑based biotech, with multiple development programs in areas of high unmet medical need such as oncology, rare diseases, and next‑generation vaccines. In these fields, economic returns are not linear: a single clinical success can have a disproportionate impact on both revenues and market capitalization.
From a technical standpoint, the price has broken above the $48.92 resistance, marking a higher high and signaling a trend change.
It is very likely that a short‑term retest will follow; if successful, it could lay the foundations for the next bullish leg toward the $64 area.
The strong increase in trading volumes over the past months suggests that this could be the year of BIOTECH, as extraordinary results are expected from the application of AI to pharmaceutical research.
As always, those who appreciate my ideas are welcome to leave a like.
Comments and alternative viewpoints are always very welcome.
Some background information:
Moderna is first and foremost a research‑driven biotechnology company, not a traditional, mature pharmaceutical firm. Its value does not depend on stable revenues or on a single product, but on its mRNA platform and its ability to turn scientific research into new therapies and vaccines.
The market today tends to view Moderna as a declining ex‑COVID stock, but this perspective underestimates its nature as a platform‑based biotech, with multiple development programs in areas of high unmet medical need such as oncology, rare diseases, and next‑generation vaccines. In these fields, economic returns are not linear: a single clinical success can have a disproportionate impact on both revenues and market capitalization.
From a technical standpoint, the price has broken above the $48.92 resistance, marking a higher high and signaling a trend change.
It is very likely that a short‑term retest will follow; if successful, it could lay the foundations for the next bullish leg toward the $64 area.
The strong increase in trading volumes over the past months suggests that this could be the year of BIOTECH, as extraordinary results are expected from the application of AI to pharmaceutical research.
As always, those who appreciate my ideas are welcome to leave a like.
Comments and alternative viewpoints are always very welcome.
Note
Price touched monthly SMA20 (orange line)Note
Watch out for the incoming retest!After an important breakout like a double bottom, a retest is inevitable before the next bullish move.
If successful, the price will head toward $64; if it fails, it will return to the lows.
Note
Flag broken, moving to next target at 64$Note
Powerful swing!
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.